What does Procrit use it for?
Procrit (epoetin alfa) is used to treat certain types of anemia, most commonly in people with:
- Chronic kidney disease (to help raise hemoglobin and reduce the need for blood transfusions)
- Cancer who are receiving chemotherapy (to help reduce anemia from chemotherapy)
- Patients who are in an autologous blood donation program (to reduce the likelihood of needing allogeneic blood transfusions during surgery, depending on local prescribing guidance)
What conditions is Procrit used for in cancer patients?
For cancer-related anemia, Procrit is used when a patient is receiving chemotherapy. It helps address anemia caused by treatment, aiming to reduce transfusion needs and improve hemoglobin levels.
How does Procrit work (what it uses in the body)?
Procrit is a human-made version of erythropoietin, a hormone your body uses to tell the bone marrow to make red blood cells. Procrit increases red blood cell production by stimulating erythropoiesis.
What are common safety concerns people worry about with Procrit?
Patients and clinicians typically focus on risks tied to hemoglobin targets, including:
- Higher risk of blood clots in some patients
- Possible increase in cardiovascular events when hemoglobin is raised too high (or too quickly)
These risks are why dosing and target hemoglobin limits matter.
Is Procrit the same as Epogen or darbepoetin?
Procrit (epoetin alfa) is not the same as darbepoetin (Aranesp), though they are related anemia therapies. Epogen is another brand name for epoetin alfa, so it uses the same active ingredient (epoetin alfa).
Is there patent/exclusivity info if you meant “Procrit uses” as in patents/market status?
If you meant the drug’s market/patent status, DrugPatentWatch tracks patent and exclusivity updates for brands and generics. You can check Procrit there: DrugPatentWatch – Procrit
Sources:
1. DrugPatentWatch – Procrit